{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-325375","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.425581+00:00","generated_at":"2026-06-28T09:59:25.027324+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Ovid Therapeutics reports Q3 2021 net loss of $11.4M, cash $201.8M, and business development strategy","bullets":["Cash and equivalents $201.8M as of Sept 30, 2021; net loss $11.4M ($0.17 per share) vs $16.4M ($0.28) in Q3 2020.","Revenue zero vs $6.9M in Q3 2020; R&D expenses down to $4.9M from $15.9M due to OV101 wind-down and soticlestat termination.","Soticlestat Phase 3 trials for Lennox-Gastaut and Dravet enrolling; Ovid eligible for up to 20% royalties on global sales.","Ovid plans to pursue business development for precision therapeutics; targets IND submission for OV329 in 2022.","Kevin Fitzgerald, Ph.D., former Alnylam CSO, appointed to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-325375","json":"https://secwatch.observer/filing/0001193125-21-325375.json","markdown":"https://secwatch.observer/filing/0001193125-21-325375.md","text":"https://secwatch.observer/filing/0001193125-21-325375.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000119312521325375/0001193125-21-325375-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000119312521325375/d245103d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:59:25.027324+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}